Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

▎药明康德优于现有疗法！Moderna流感mRNA疫苗3期结果积极Moderna今日公布其季节性流感mRNA疫苗mRNA-1010在3期临床研究（P304）积极进展。该研究在50岁及以上的成人群体中评估了mRNA-1010相较于获批标准剂量季节性流感 ...

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

Moderna 的季节性流感 mRNA 疫苗 mRNA-1010 在 III 期试验中展现出显著优势 —— 在 50 岁及以上人群中，其预防流感的效果比现有标准剂量疫苗高出 26.6%。这项覆盖 11 个国家、超 4 万名受试者的研究显示，65 岁以上老年人群的保护效力提升更为明显，达 27.4%。细分病毒株数据进一步验证其优势：对 A/H1N1 株保护效力提高 29.6%，A/H3N2 株提高 ...

Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

近年来，流感疫苗的研发一直是公众和医学界关注的热点。随着Moderna公司最新的季节性流感mRNA疫苗mRNA-1010在III期临床试验中取得显著成果，流感疫苗的未来似乎迎来了新的曙光。这项覆盖11个国家、超过4万名受试者的研究结果显示，mRNA-1010在50岁及以上人群中的预防效果比现有的标准剂量疫苗高出26.6%。对于65岁以上的老年人群体，其保护效力更是提升至27.4%。这一数据不仅让人 ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

周二，美股医药板块逆市走高，截至发稿，Moderna (MRNA.US)涨超1.6%，礼来 (LLY.US)涨0.85%，诺和诺德 (NVO.US)涨超1.2%，联合健康 (UNH.US)涨超3.9%，辉瑞 (PFE.US)涨超3.4%。消息面上，此前Moderna宣布其mRNA流感疫苗 ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Moderna美股盘前涨超6%。 一周牛熊股丨15股周涨超40%，最牛股周涨超95% 一周牛熊股丨15股周涨超40%，最牛股周涨超95% 一周牛熊股 ...